T2 Biosystems (NASDAQ:TTOO) Now Covered by StockNews.com

Equities researchers at StockNews.com began coverage on shares of T2 Biosystems (NASDAQ:TTOO) in a note issued to investors on Sunday. The firm set a “sell” rating on the medical equipment provider’s stock.

T2 Biosystems Stock Performance

TTOO stock opened at $0.41 on Friday. The firm has a 50 day moving average price of $0.53 and a 200-day moving average price of $2.44. T2 Biosystems has a 52-week low of $0.31 and a 52-week high of $6.95.

Institutional Trading of T2 Biosystems

A hedge fund recently bought a new stake in T2 Biosystems stock. Armistice Capital LLC purchased a new stake in shares of T2 Biosystems, Inc. (NASDAQ:TTOO) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,658,000 shares of the medical equipment provider’s stock, valued at approximately $8,854,000. Armistice Capital LLC owned approximately 9.49% of T2 Biosystems as of its most recent SEC filing. 23.18% of the stock is owned by institutional investors.

T2 Biosystems Company Profile

T2 Biosystems, Inc, an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.